GT Biopharma to Present at Centurion One Capital Conference: A Look into the Future of Immuno-Oncology Therapeutics
ByAinvest
Tuesday, Feb 17, 2026 7:31 am ET1min read
GTBP--
GT Biopharma, a clinical-stage immuno-oncology company, announced that Michael Breen, Executive Chairman and CEO, will present at the Centurion One Capital 9th Annual Toronto Growth Conference on March 5th, 2026. The Company will be available for one-on-one meetings and will discuss its proprietary TriKE® natural killer cell engager platform, which aims to enhance the cancer-killing abilities of the immune system's natural killer cells.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet